Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 582 1199

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

BankingWithSeven Sep. 12 at 8:57 PM

Looks like ALL volume and momentum are shifting in to CMCT! Shorts overextended and now bulls can have them trapped at the bottom. CMCT Could pull a huge multi day run - only 700k float! Don't miss CMCT..,it's breaking out! $ATCH $SMX $ERNA $STAI nd

0 · Reply

Dieseld28 Sep. 11 at 1:44 PM

$ERNA $5

0 · Reply

Tusto Sep. 9 at 10:45 AM

$ERNA Under a dollar soon. Next RS and new name for this scam. That what they do.

0 · Reply

Russell007xx Sep. 4 at 4:56 PM

$ERNA the scam continues, up 1% down 10%, up % then down 20% and that’s how they brought down 90% down and then to cover up you need 300-400% % up just to be even and which never happens

0 · Reply

NVDAMillionaire Sep. 3 at 10:32 AM

$ERNA Outstanding article that hits the mark on ERNA's current state. So if you want to refresh your ERNA insights or learn about ERNA from scratch, this is a must read. https://beyondspx.com/quote/ERNA/ernexa-therapeutics-unlocking-off-the-shelf-cell-therapies-for-cancer-and-autoimmune-disease-nasdaq-erna#analysis

0 · Reply

Russell007xx Sep. 2 at 12:18 PM

$ERNA today we will see another 52 week low

0 · Reply

Love_To_Learn Aug. 29 at 11:44 AM

$ERNA need u today

0 · Reply

Tusto Aug. 28 at 6:29 PM

$ERNA this scam is now called Emexa therapeutics inc. Other name same scam as always.

0 · Reply

WNBEMILLNRE Aug. 28 at 3:29 PM

$ERNA My average cost is $240.77. Someday…

0 · Reply

Russell007xx Aug. 27 at 8:02 PM

$ERNA another 52 week low

0 · Reply

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 3, 2025, 9:30 AM EDT - 9 days ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Jul 9, 2025, 8:30 AM EDT - 2 months ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 25, 2025, 8:30 AM EDT - 2 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 24, 2025, 8:30 AM EDT - 2 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 10, 2025, 9:30 AM EDT - 3 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

May 28, 2025, 8:30 AM EDT - 3 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 14, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 8, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 29, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 5 months ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 3, 2025, 8:55 AM EDT - 5 months ago

Ernexa Therapeutics Closes New Funding Round

Feb 26, 2025, 8:30 AM EST - 7 months ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Jan 14, 2025, 8:30 AM EST - 8 months ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 9, 2025, 7:30 AM EST - 8 months ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Nov 14, 2024, 8:30 AM EST - 10 months ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Oct 30, 2024, 8:30 AM EDT - 11 months ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 17, 2024, 8:00 AM EDT - 11 months ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

May 10, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 8, 2024, 9:31 AM EDT - 1 year ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Feb 20, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Jan 3, 2024, 4:15 PM EST - 1 year ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Dec 20, 2023, 4:15 PM EST - 1 year ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 14, 2023, 6:56 PM EST - 1 year ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

May 24, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 17, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023, 7:30 AM EDT - 2 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Mar 20, 2023, 4:10 PM EDT - 2 years ago

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Feb 22, 2023, 8:00 AM EST - 2 years ago

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Jan 4, 2023, 8:30 AM EST - 2 years ago

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

Dec 20, 2022, 8:05 AM EST - 2 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics

Nov 1, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

Oct 18, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

Oct 17, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

BankingWithSeven Sep. 12 at 8:57 PM

0 · Reply

Dieseld28 Sep. 11 at 1:44 PM

$ERNA $5

0 · Reply

Tusto Sep. 9 at 10:45 AM

$ERNA Under a dollar soon. Next RS and new name for this scam. That what they do.

0 · Reply

Russell007xx Sep. 4 at 4:56 PM

$ERNA the scam continues, up 1% down 10%, up % then down 20% and that’s how they brought down 90% down and then to cover up you need 300-400% % up just to be even and which never happens

0 · Reply

NVDAMillionaire Sep. 3 at 10:32 AM

0 · Reply

Russell007xx Sep. 2 at 12:18 PM

$ERNA today we will see another 52 week low

0 · Reply

Love_To_Learn Aug. 29 at 11:44 AM

$ERNA need u today

0 · Reply

Tusto Aug. 28 at 6:29 PM

$ERNA this scam is now called Emexa therapeutics inc. Other name same scam as always.

0 · Reply

WNBEMILLNRE Aug. 28 at 3:29 PM

$ERNA My average cost is $240.77. Someday…

0 · Reply

Russell007xx Aug. 27 at 8:02 PM

$ERNA another 52 week low

0 · Reply

TokenizedSecurities Aug. 27 at 4:20 AM

$ERNA trending upward but showing signs of exhaustion, needs confirmation.

0 · Reply

Russell007xx Aug. 25 at 10:43 PM

$ERNA lol every day 52 weeks low

0 · Reply

Chickendinner1 Aug. 22 at 12:18 AM

$ERNA drop some news. About go below 1.50

0 · Reply

BigSqueezeComing Aug. 19 at 9:48 PM

$ERNA ah movers.

0 · Reply

Tusto Aug. 14 at 11:45 AM

$ERNA Heading for another RS and maybe a new name for this scam company. That's all they do. RS, dilution and a new name to start the whole scam cycle again.

0 · Reply

Tusto Aug. 1 at 7:22 PM

$ERNA is a scam. RS, dilution and change name is all these f@ckers do

0 · Reply

Chickendinner1 Jul. 31 at 11:25 AM

$ERNA it will run 200% when they drop news

1 · Reply

Chickendinner1 Jul. 29 at 3:31 PM

$ERNA it is just painful af

0 · Reply

ChartChartist Jul. 27 at 7:11 PM

$ERNA with them fuxing notes, need support to show $UCAR yes baby!! Get them flips in. Noones holding these small caps $TPST thats called a candle combo. Looks rockin ✔️ $OLB everyones talking about this beauti lets see it launch monday 4am

0 · Reply

Russell007x Jul. 25 at 1:41 PM

$ERNA wtf?🤬 Management is trying to screw us again?

0 · Reply

Russell007x Jul. 25 at 1:17 PM

0 · Reply

50shadesoftrades Jul. 24 at 7:43 PM

$ERNA lots of vol came in earlier, chart setting up..

0 · Reply

Market Cap	1.43M
Revenue (ttm)	580,000.00
Net Income (ttm)	-44.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,679.31%
Debt to Equity Ratio	0.00

Volume	359,085
Avg Vol	12,707,749
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	48%
Beta	4.47
Analysts	Hold
Price Target	N/A